Adam K. Simpson - 25 Jan 2023 Form 4 Insider Report for Icosavax, Inc.

Role
Chief Executive Officer, Director
Signature
/s/ Elizabeth Bekiroglu, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
25 Jan 2023
Net transactions value
+$13,117
Form type
4
Filing time
27 Jan 2023, 16:02:56 UTC
Previous filing
23 Dec 2022
Next filing
15 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ICVX Common Stock Options Exercise $2,012 +2,395 +1% $0.8400* 241,869 25 Jan 2023 Direct
transaction ICVX Common Stock Options Exercise $11,105 +10,678 +4.4% $1.04* 252,547 25 Jan 2023 Direct
holding ICVX Common Stock 531,576 25 Jan 2023 By family trust
holding ICVX Common Stock 129,032 25 Jan 2023 By family trust
holding ICVX Common Stock 129,032 25 Jan 2023 By family trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ICVX Stock Option (Right to Buy) Options Exercise $0 -2,395 -7.1% $0.000000 31,132 25 Jan 2023 Common Stock 2,395 $0.8400 Direct F1
transaction ICVX Stock Option (Right to Buy) Options Exercise $0 -10,678 -2.4% $0.000000 427,927 25 Jan 2023 Common Stock 10,678 $1.04 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the option vested on 2/21/2021, and 1/48th of the shares subject to the option vest monthly thereafter.
F2 25% of the shares subject to the option vested on 1/14/2022, and 1/48th of the shares subject to the option vest monthly thereafter.